The National Lung Screening Trial (NLST) showed the promise of annual low-dose CT (LDCT) screening for lung cancer: a 20% relative reduction in lung cancer death for individuals at high risk of developing cancer based on their age and smoking history. 1 The NLST was a well-designed, well-conducted clinical trial carried out in academic centers known for their excellence in medical imaging and cancer care. The NLST achieved high rates of adherence to recommended next steps after the initial screening LDCT scan, with > 93% of positive screens leading to a diagnostic test, and 95% adherence to yearly screening LDCT scans. Similar attention to timely and appropriate evaluation of screen-detected pulmonary nodules, including judicious use of invasive procedures, will presumably be required in real-world practice to replicate the NLST's reduction in lung cancer death. Accordingly, policy statements guiding implementation of high-quality lung cancer screening have emphasized the importance of algorithms to ensure appropriate evaluation of screen-detected nodules. [2] [3] [4] [5] 
The National Lung Screening Trial (NLST) showed the promise of annual low-dose CT (LDCT) screening for lung cancer: a 20% relative reduction in lung cancer death for individuals at high risk of developing cancer based on their age and smoking history. 1 The NLST was a well-designed, well-conducted clinical trial carried out in academic centers known for their excellence in medical imaging and cancer care. The NLST achieved high rates of adherence to recommended next steps after the initial screening LDCT scan, with > 93% of positive screens leading to a diagnostic test, and 95% adherence to yearly screening LDCT scans. Similar attention to timely and appropriate evaluation of screen-detected pulmonary nodules, including judicious use of invasive procedures, will presumably be required in real-world practice to replicate the NLST's reduction in lung cancer death. Accordingly, policy statements guiding implementation of high-quality lung cancer screening have emphasized the importance of algorithms to ensure appropriate evaluation of screen-detected nodules. [2] [3] [4] [5] So how do rates of follow-up testing in real-world practice compare with the standard set in the NLST? In this issue of CHEST, Nishi et al 6 provide preliminary insight into this question by analyzing claims from a national commercial insurance database. The study assesses the frequency of diagnostic imaging and procedures among 11,520 patients in the 12 months after LDCT screening, comparing these rates with those reported in the NLST. Nishi et al 6 found relatively low rates of diagnostic imaging after screening, estimated at 13.8% to 17.7%, compared with 21.7% in the NLST. By contrast, they found higher rates of invasive procedures (overall 3.1%-3.7%) compared with the NLST, with nearly double the rates of bronchoscopy and triple the rates of percutaneous biopsy and thoracoscopy.
How should these findings be interpreted? On the face of it, one might be concerned that rates of follow-up imaging appear low, suggesting that patients with screen-detected nodules may not be receiving guidelinerecommended surveillance imaging, a phenomenon well documented in the setting of incidental pulmonary nodules, in which only one-half of patients receive guideline-concordant evaluation. 7 However, this may not necessarily be the case. Since the publication of the NLST, the Lung-RADS system has come into widespread use, a system which standardizes reporting of screen-detected findings, raising the threshold for a positive test requiring surveillance imaging. Applying the Lung-RADS criteria to the NLST cohort results in fewer positive findings and fewer recommended followup imaging tests. 8 Therefore, the lower rate of follow-up imaging observed in the Nishi et al 6 study may simply reflect use of Lung-RADS. That being said, even with use of the Lung-RADS criteria, rates of positive scans that prompt recommendations for follow-up imaging have been higher in real-world cohorts than in the NLST. 9 The bottom line is it is impossible to interpret whether the rate of follow-up imaging observed in the Nishi et al 6 real-world study is appropriate without knowing the screening results.
Although it is likewise difficult to comment on the expected rate of invasive procedures without knowing the underlying screening test results, the finding of higher rates of invasive procedures is concerning. Because of the potential harms associated with invasive procedures (eg, bleeding, pneumothorax, even death), clinical practice guidelines recommend reserving invasive procedures for nodules with a moderately high pretest probability of cancer. Despite these guidelines, in the incidental pulmonary nodule setting, rates of invasive procedures vary widely 10 but are consistently higher than recommended. 11 Given that complication rates of invasive procedures for pulmonary nodules are also consistently higher in community settings than in clinical trials, 10, 12 overly aggressive use of invasive testing for screen-detected nodules could substantially increase the harms associated with lung cancer screening.
This study assesses diagnostic follow-up rates in a 12month period after a single LDCT screen. However, current guidelines recommend yearly screening for up to 26 years for those eligible for screening. 3, 4 As such, we must consider the rates of follow-up imaging and invasive diagnostic procedures over the entire course of a patient's exposure to LDCT screening. The Nishi et al 6 study reports that 3.1% to 3.7% of patients underwent an invasive procedure in just the first year after screening compared with an invasive procedure rate of 4.2% from 3 years of screening in the NLST. 13 How this number changes when a patient is exposed to 15, 20, or the full 26 years of screening will greatly impact the overall balance of harms and benefits of screening.
Finally, an important consideration that could not be measured in the study by Nishi et al 6 is how an individual patient's values and preferences might influence the timing and type of diagnostic follow-up for a screen-detected nodule. There is clinical equipoise in how to manage indeterminate pulmonary nodules, with both surveillance imaging and invasive testing considered appropriate options for nodules with an intermediate pretest probability of cancer, depending on the patient's values and preferences. 14 Shared decisionmaking is a critical component when first determining whether a patient should initiate screening, [2] [3] [4] and it becomes essential again in the event of a positive screen in determining appropriate evaluation that best matches the patient's values and preferences. The extent to which shared decision-making is incorporated into real-world practice in determining next steps after a screendetected nodule is currently unknown.
The study by Nishi et al 6 raises questions as to whether LDCT screening is being implemented in the way it was intended, and given the limited conclusions that can be drawn from this claims-based analysis alone, it perhaps raises more questions than provides answers. As we continue to implement lung cancer screening in real-world settings, we must be vigilant in striving to optimize the balance of benefits and harms. This will require not only assessing concordance with guideline recommendations in the decision to initiate screening, but also appropriateness of physician recommendations for and patient adherence to the diagnostic evaluation of screen-detected nodules.
